{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T08:32:06Z","timestamp":1792139526656,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"am","delay-in-days":411,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA16672"],"award-info":[{"award-number":["P30 CA16672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"The University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.04.015","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:55:25Z","timestamp":1752616525000},"page":"1010-1019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis"],"prefix":"10.1016","volume":"8","author":[{"given":"Amado J.","family":"Zurita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Tidwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Chapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah R.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis L.","family":"Pisters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Arce-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Troncoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.04.015_b0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.04.015_b0010","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.04.015_b0015","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2017.08.011","article-title":"Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis","volume":"73","author":"Seisen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.015_b0020","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.eururo.2018.10.042","article-title":"Which patients with clinically node-positive prostate cancer should be considered for radical prostatectomy as part of multimodal treatment? The impact of nodal burden on long-term outcomes","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.015_b0025","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.04.015_b0030","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv119","article-title":"Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer","volume":"107","author":"Lin","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 5","key":"10.1016\/j.euo.2025.04.015_b0035","article-title":"855PD - Docetaxel for hormone-naive prostate cancer (PCa): results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial","volume":"30","author":"James","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.04.015_b0040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.euo.2019.02.001","article-title":"A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer","volume":"2","author":"Ventimiglia","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.04.015_b0045","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.04.015_b0050","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.04.015_b0055","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): prostate cancer (version 4.2024). Plymouth Meeting, PA: NCCN; 2024."},{"key":"10.1016\/j.euo.2025.04.015_b0060","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2009.12.034","article-title":"Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer","volume":"57","author":"Engel","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.015_b0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2015.07.047","article-title":"Outcomes for patients with clinical lymphadenopathy treated with radical prostatectomy","volume":"69","author":"Moschini","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.015_b0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/pcan.2015.23","article-title":"Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer","volume":"18","author":"Zurita","year":"2015","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2025.04.015_b0075","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2015.65.3154","article-title":"A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy","volume":"34","author":"McKay","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.015_b0080","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1158\/1078-0432.CCR-19-2389","article-title":"A phase II study of cabozantinib and androgen ablation in patients with hormone-naive metastatic prostate cancer","volume":"26","author":"Corn","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.015_b0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2012.48.5268","article-title":"Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer","volume":"32","author":"Michaelson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.015_b0090","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1200\/JCO.2015.65.5597","article-title":"Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1","volume":"34","author":"Smith","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.euo.2025.04.015_b0095","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1470-2045(25)00209-8","article-title":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","volume":"26","author":"Agarwal","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.04.015_b0100","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.015_b0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1158\/1078-0432.CCR-15-0235","article-title":"Integrating murine and clinical trials with cabozantinib to understand roles of MET and VEGFR2 as targets for growth inhibition of prostate cancer","volume":"22","author":"Varkaris","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.015_b0110","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-16-0778","article-title":"Cabozantinib eradicates advanced murine prostate cancer by activating antitumor innate immunity","volume":"7","author":"Patnaik","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2025.04.015_b0115","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/bjc.2016.29","article-title":"Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition","volume":"114","author":"Byrne","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2025.04.015_b0120","doi-asserted-by":"crossref","first-page":"E263","DOI":"10.1152\/ajpendo.00210.2010","article-title":"Androgen deprivation induces rapid involution and recovery of human prostate vasculature","volume":"300","author":"Godoy","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.euo.2025.04.015_b0125","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/00000478-200310000-00001","article-title":"A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume","volume":"27","author":"Chen","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euo.2025.04.015_b0130","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.015_b0135","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.eururo.2009.10.020","article-title":"Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification","volume":"57","author":"Efstathiou","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.015_b0140","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.04.015_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.euo.2025.04.015_b0150","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bju.15055","article-title":"The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer","volume":"125","author":"Ranasinghe","year":"2020","journal-title":"BJU Int"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:25:42Z","timestamp":1762629942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001063"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.015","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}